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Anthrax is one of the oldest threats to humankind, and remains endemic in animals in
many parts of the world. Human cases are infrequent, and some result from biological
warfare. This review summarizes the current knowledge on the antibacterial activity of
available antibiotics. For potential use in the most severe cases of anthrax, antibacterials
need to exhibit potent in vitro activity, intracellular bioactivity, and suitable locations in
lymph nodes. In animal models, it has been shown that doxycycline and fluoroquino-
lones are the most active compounds. There is a lack of data for animal models for
macrolides and ketolides, some of them exhibiting good in vitro activity. However,
systemic anthrax (inhalation or gastrointestinal) is mainly due to anthrax toxin, and
therapy directed against intoxication is needed as basic treatment.
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I N T R O D U C T I O N
Anthrax is one of the oldest documented infectious
diseases and is believed to be the fifth Egyptian
plague at the time of Moses, described in the book
of Genesis (Exodus 9); clinical cases were also
clearly reported by the ancient Romans and
Hindus. In 25 BC, Virgil, in the third Georgic
Period, described the illness [1]. Anthrax was
probably the disease behind the ‘Black Bane’
which swept through Europe in the Middle Ages,
causing a large number of human and animal
deaths. A panzootic of anthrax that killed approxi-
mately one-half of the sheep in Europe in the
mid-1800s resulted in intensive research by early
microbiologists. Rayer, in 1850 [2], showed that
administration of anthrax-contaminated blood
containing ‘small bodies’ from a sick animal could
induce anthrax in healthy sheep. This observation
was confirmed in 1855, by Pollender [3], who was
unable to prove the involvement of these organ-
isms in anthrax. Davaine demonstrated in 1868
that the ‘bacteridia’ is the causative agent of
anthrax [4]. In 1877, Bacillus anthracis was isolated
in pure culture from the vitreous humour of a
bovine eye and was proved to be the anthrax
etiologic agent by Robert Koch [5–7]. Louis Pasteur
in 1881 [8] and William Greenfield in 1880 [9] were
pioneers in anthrax vaccination [10].
B. anthracis is a Gram-positive spore-forming
bacillus; it is the etiologic agent of anthrax.
Anthrax commonly occurs in both wild and
domestic mammals (e.g. sheep, cattle, horses, pigs,
goats, camels, antelopes, bison, elephants, hippo-
tami, kudu, and other herbivores) [11]. The results
of studies of agricultural outbreaks have sug-
gested that conditions for multiplication are favor-
able when the soil has a pH above 6.0 and is rich in
organic matter [12].
Humans can develop anthrax infection follow-
ing exposure to the organism through infected
animals or tissue from infected animals, or by
direct exposure to B. anthracis [13,14]. Sporadic
outbreaks have occurred as a result of both agri-
cultural and military disruptions. Anthrax is ende-
mic in rural India [15], Pakistan, Sudan and Egypt,
as well as in many parts of Asia.
In the last 25 years, only a few major outbreaks
have occurred. The first was in Zimbabwe in 1979–
80, during the Rhodesian civil war, when failure of
veterinary vaccination programs led to a human
epidemic, causing 6500 anthrax cases and 200 fatal-
ities [16]. The second outbreak was in Paraguay in
1980 [17]. In France, some human cases were
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reported in 1997, as well as two animal anthrax
outbreaksintwoareas[18].Anaccidentintheformer
Soviet Union in the research center at Sverdlosk
(Ekateringburg) led to the death of 66 adults due
to inhaled anthrax [19]. Sixteen anthrax cases in
humans were recorded in the UK between 1980
and 2000; all were cutaneous cases, and associated
with workers who handled bone meal, animal car-
casses and skin [20]. Twenty-five human cases
of anthrax occurred between 1978 and 1981 in
Switzerland in textile workers handling infected
goat hair from Pakistan [21]. In 1992, a family out-
break of anthrax was reported in northern Italy [22].
In 1971, outbreaks were reported in sub-Saharan
Africa—(Chad) [23] and The Gambia—due to the
use of communal loofahs when bathing [24]. In
Thailand, a gastrointestinal anthrax outbreak was
reported after ingestion of contaminated water-
buffalo meat [25].
In the USA, the microorganism remains endemic
in the soil of Texas, Oklahoma, and the lower Mis-
sissippi [26]. Since 1974, due to the risk of contam-
ination, importation of goat skins have been banned
in the USA from Haiti [20,27]. In the USA, from 1955
to 1987, there were 233 human cases of anthrax, and
before the current crisis following the atrocities of 11
September 2001, the last human report was pub-
lished in August 2001, in which one patient was
exposed to B. anthracis during an epizootic anthrax
among livestock in North Dakota [28]. Anthrax has
beenreportedindeerintheUSAandinwoodbuffalo
in Canada [20].
Anthrax was used as a biological weapon for the
first time by Moses. In the 20th century, Germany
developed plans during World War I to contam-
inate sheep herds from Romania. In 1917–18, in
Argentina, livestock destined for the Allied forces
was infected with anthrax and B. mallei (glanders),
resulting in the death of more than 200 mules [29].
Japan conducted biological warfare experiments
in Manchuria from 1932 to 1945. In Unit 731,
located near the town of Ping Fan, prisoners were
infected with B. anthracis and other biological
organisms [30]. The Japanese also deliberately
contaminated water supplies and food with B.
anthracis. In 1941–42, to be prepared for retaliation
against German biological weapons, the British
carried out bomb experiments with weaponized
spores of B. anthracis on Gruinard Island near the
coast of Scotland. Viable spores of anthrax per-
sisted for 45 years after World War II, until 1986
when the island was decontaminated with formal-
dehyde and sea water [31]. From the 1950s to 1970,
the USA experimented with biological weapons,
including anthrax spores, until President Nixon
terminated the program.
A Japanese terrorist group (Aum Shirikyo) dis-
persed anthrax aerosols in Tokyo subway stations
on many occasions in 1995 without succeeding to
induce anthrax, due to the fact that they used the
avirulent (non-capsulated) strain ‘Sterne’ [20,32].
During the Gulf War, it was clearly demonstrated
that Iraq possesses anthrax as a biological weapon.
At least three clinical pictures can be described:
cutaneous infection, gastrointestinal infection, and
inhaled (pulmonary disseminated infection). There
have been no reports in the literature of direct
human-to-human transmission. Most cases in in-
dustrialized countries are associated with exposure
to animal products, especially goat hair imported
from Turkey, Sudan and Pakistan, where anthrax
remains common among domestic livestock.
A N T I B A C T E R I A L A C T I V I T Y O F
A N T I B I O T I C S
In vitro activity of antibacterial agents
In the different studies carried out to investigate
the in vitro susceptibility of B. anthracis to various
antibacterial agents, there has been variation in the
methodologies used to determine MICs.
In the studies of Heine et al. [33,34], the micro-
broth dilution method in cation-adjusted Mueller–
Hinton was used. The strains were added in
microwells in the log growth phase at an inoculum
of 5 104 CFU/mL. In the CDC study [35], strains
were grown on TSA blood agar and an inoculum
adjusted to 0.5 MacFarland was prepared in Muel-
ler–Hinton broth. MICs were determined in micro-
broth cation-adjusted Mueller–Hinton. When
comparing MICs from both studies, there is an up
to two doubling dilution difference, especially for
ciprofloxacin, chloramphenicol, and doxycycline,
but not for penicillin G. In other studies, MICs were
determined using an agar dilution method, with
incubation at 37 8C overnight in ambient air [36,37].
It has been shown that, with b-lactam antibiotics,
the percentage of spores in the inoculum did not
influence MICs of benzylpenicillin, amoxicillin, and
amoxicillin–clavulanate (Heine, personal commu-
nication). However, available antibacterials against
B. anthracis are not active against spores.
B. anthracis KC-1 was tested for its susceptibility
to all new investigational compounds (Tables 1
468 Clinical Microbiology and Infection, Volume 8 Number 8, 2002
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 467–478
and 2) at Kyoto University (Japan). The KC-1 strain
is highly susceptible to benzylpenicillin and ampi-
cillin or amoxicillin, but less susceptible to N-acyl-
or a-sulfopenicillins. Even if some oral cephems,
such as cefaclor or cefadroxil, display high in vitro
activity, all the cephems have low activity or are
inactive against B. anthracis. Flomoxef, an oxa-1-
cephamycin, displays interesting activity, with an
MIC of 0.2 mg/L, in comparison with latamoxef,
which has an MIC of 1.56 mg/L. Among carbape-
nems, panipenem seems to be highly active, as
well as imipenem, with low MICs. Aminoglyco-
sides have low activity. Vancomycin has low activ-
ity, but teicoplanin seems to exhibit good in vitro
activity, with an MIC of 0.20 mg/L. In the macro-
lide field, clarithromycin exhibits the highest activ-
ity, and other compounds share similar
antibacterial activity. Fluoroquinolones are highly
active; however, lomefloxacin, fleroxacin, enoxa-
cin and norfloxacin are less active. MICs were
determined using brain–heart infusion agar with
an inoculum size of 106 CFU/mL. An inoculum
effect has been demonstrated with b-lactams when
increasing the size of inoculum from 106 to
108 CFU/mL.
In other studies, more isolates have been tested,
collected from different sources. In a study pub-
lished in 1991, 22 isolates collected from cutaneous
anthrax cases were shown to be highly susceptible
to penicillin G, ampicillin, ofloxacin and ciproflox-
acin (Table 3) [36]. In a second study, 70 isolates
were tested, demonstrating good activity of benzyl-
Table 1 In vitro activity of b-lactam and aminoglycoside
antibiotics against Bacillus anthracis
Antibiotics MIC (mg/L)
Benzylpenicillin 0.015
Amoxicillin 0.025
Ampicillin 0.025
Piperacillin 0.78
Sulbenicillin 0.78
Cefaclor 0.78
Cefadroxil 0.78
Cephalexin 1.56
Cefuroxime 25
Cefixime >100
Cefetamet 100
Cefteram 6.25
Ceftibuten >100
Cefpodoxime 6.25
Cefdinir 1.56
Cefditoren 6.25
Cefazolin 0.09
Cefoperazone 1.56
Cefpimizole 12.5
Cefotaxime 6.25
Ceftriaxone 12.5
Ceftizoxime 25
Cefmenoxime 12.5
Cefotiam 3.13
Ceftazidine 50
Cefepime 12.5
Cefpirome 12.5
Cefsulodin 50
Cefodizime 25
Latamoxef 1.56
Flomoxef 0.20
Cefminox 3.13
Imipenem 0.012
Panipenem 0.006
Ritipenem 0.10
Aztreonam >100
Carumonam >100
Gentamicin 1.56
Netilmicin 1.56
Amikacin 6.25
Dibekacin 3.12
Arbekacin (souche TMS-1) 3.12
Adapted from Nishino et al. Chemotherapy (Tokyo).
Numerous supplements on new antibacterials.
Table 2 In vitro activity of fluoroquinolones, macrolides
and other antibacterials against Bacillus anthracis KC-1
Antibiotics MIC (mg/L)
Erythromycin A 0.20
Roxithromycin 0.39
Azithromycin 0.39
Clarithromycin 0.10
Josamycin 0.20
Midecamycin 0.39
Miokamycin 0.78
Rokitamycin 0.20
Leucomycin 0.39
Dalfopristin–quinupristin 0.20
Teicoplanin 0.20
Vancomycin 1.56
Minocycline 0.10
Nalidixic acid 6.25
Pipemidic acid 1.56
Miloxacin 3.13
Norfloxacin 0.39
Ofloxacin 0.10
d-ofloxacin 0.10
Levofloxacin 0.05
Sparfloxacin 0.05
Tosufloxacin 0.01
Pazufloxacin 0.05
Balofloxacin 0.05
Lomefloxacin 0.20
Enoxacin 0.39
Fleroxacin 0.39
Grepafloxacin 0.025
Adapted from Nishino et al. Chemotherapy (Tokyo).
Numerous supplements on new antibacterials.
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penicillin and amoxicillin; however, two isolates
were highly resistant to penicillin G (MIC 64 mg/
L), tetracycline and ciprofloxacin (Table 3) [37].
In vitro, B. anthracis is susceptible to rifampicin
(MIC 0.5 mg/L); however, in an in vivo murine
model, oral rifampicin caused only an increase in
mean lifespan and had no significant effect on
survival rate [38]. Recently, the antibacterial sus-
ceptibilities of the isolates related to the recent
infections in the USA, as well as other data, were
released from the CDC [33–35,39] (Table 3).
A working group on MIC harmonization for B.
anthracis was set up at the NCCLS subcommittee
meeting, held in January 2002 in Tampa (Florida),
Table 3 In vitro susceptibility of Bacillus anthracis
MIC (mg/L)
Compounds N 50 90 Range References
Ciprofloxacin 65 0.06 0.06 0.03–0.12 [35]
28 0.03 0.03 0.01–0.125 [39]
96 0.06 0.06 0.03–0.06 [37]
22 0.06 0.06 0.03–0.06 [37]
18 0.25 2.0 0.06–0.2 [34]
Levofloxacin 1
96 0.125 0.25 0.03–2.0 [37]
18 0.25 1.0 0.06–2.0 [34]
Gatifloxacin 1 – – 0.025 [44]
20 0.12 0.12 0.12 [35]
96 0.12 0.12 0.12
Trovafloxacin 1 – – 1.6 [44]
Pefloxacin 96 0.125 0.5 0.03–1.0 [37]
Nalidixic acid 96 4.0 8.0 0.03–32 [37]
Ofloxacin 96 0.25 0.25 0.03–1.0 [37]
22 0.06 0.06 0.03–0.06 [36]
18 1.0 2.0 0.5–8.0 [34]
Sparfloxacin 18 0.5 0.5 0.12–2.0 [33]
Clarithromycin 28 0.125 0.125 0.06–0.125 [39]
18 0.5 1.0 0.25–2.0 [33]
Erythromycin A 28 1.0 2.0 0.5–8.0 [39]
65 1.0 1.0 0.5–1.0 [35]
12 0.5 0.5 0.5 Data on file, 1997
70 0.5 1.0 0.25–1.0 [37]
96 1.0 1.0 1.0–4.0 [37]
Azithromycin 12 1.0 1.0 0.5–2.0 Data on file, 1997
18 8.0 8.0 2.0–8.0 [33]
Telithromycin 96 0.03 0.25 0.03–1.0 Data on file, 2001
12 0.25 0.25 0.03–0.25 Data on file, 1997
ABT 773 28 0.03 0.03 0.01–0.125 [39]
Clindamycin 64 0.5 1.0 0.5–1.0 [35]
18 0.25 0.5 0.12–1.0 [33]
96 0.12 0.25 0.25–1.0 [37]
Roxithromycin 12 0.5 0.5 0.25–1.0 Data on file, 1997
Quinupristin–dalfopristin 18 1.0 1.0 0.12–0.5 [33]
Linezolid 18 2.0 4.0 1.0–8.0 [34]
Penicillin G 65 0.06 0.06 0.06–128 [35]
70 0.06 0.125 0.01–64 [37]
18 64 >64 2.0 to >64 [33]
96 0.12 8.0 0.12–16 [37]
Ceftriaxone 74 16 32 4.0–32 [35]
18 16 64 16 to >64 [33]
Ampicillin 22 0.03 0.03 0.01–0.03 [36]
18 64 >64 4.0 to >64 [33]
Ampicillin–sulbactam 22 0.01 0.01 0.01–0.03 [36]
Amoxicillin 70 0.06 0.125 0.01–64 [37]
22 0.01 0.01 0.01–0.03 [36]
18 64 >64 8.0 to >64 [33]
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Table 3 continued
MIC (mg/L)
Compounds N 50 90 Range References
96 0.12 4.0 0.12–16 [37]
Amoxicillin–clavulanic acid 22 0.01 0.01 0.01 [36]
18 1.0 2.0 0.5–16 [33]
Piperacillin 22 0.25 0.5 0.125–0.5 [36]
18 64 >64 16 to >64 [33]
96 1.0 1.0 0.25–32 [37]
Mezlacillin 22 0.06 0.06 0.01–0.06 [36]
Cefazolin 22 0.01 0.01 0.01–0.03 [36]
0.5 1.0 1.0 0.5–8.0 [33]
Cephalothin 96 0.5 16 0.12–32 [37]
Cefuroxime 22 64 64 16–64 [36]
18 64 >64 16 to >64 [33]
70 32 64 1.0–64 [37]
Imipenem 18 0.03 0.12 0.03 to >64 [33]
96 0.12 0.12 0.12–2.0 [37]
Meropenem 18 0.06 0.12 0.03–012 [33]
Rifampicin 65 0.25 0.5 0.25–0.5 [35]
18 0.5 0.5 0.03–1.0 [33]
96 0.12 0.12 0.12–2.0 [37]
GAR-936 18 0.12 0.5 <0.03–0.5 [34]
Doxycycline 18 0.06 0.12 <0.03–0.25 [34]
96 0.12 0.12 0.12–0.25 [37]
Tetracycline 65 0.03 0.06 0.03–0.06 [35]
70 0.125 0.125 0.06–1.0 [37]
Chloramphenicol 74 4.0 4.0 2.0–8.0 [35]
22 2.0 2.0 1.0–2.0 [36]
18 16 16 8.0–64 [33]
70 4.0 4.0 2.0–4.0 [37]
96 2.0 2.0 1.0–4.0 [37]
Vancomycin 74 2.0 2.0 0.5–2.0 [35]
22 1.0 1.0 0.25–1.0 [36]
18 2.0 2.0 1.0–4.0 [34]
Teicoplanin 96 0.25 0.5 0.12–2.0 [37]
Daptomycin 18 2.0 2.0 1.0–4.0 [33]
Novobiocin 18 2.0 2.0 1.0–4.0 [33]
Clofazimine 18 16 32 8.0–64 [33]
Co-trimoxazole 22 3.2/16 3.2/16 1.6/8–3.2/16 [36]
18 >64 >64 2.0 to >64 [33]
96 >4/76 >4/76 >4/76 [37]
Sulfamethoxazole 18 >64 >64 >64 [33]
Trimethoprim 18 >64 >64 64 [33]
Oritavancin 18 0.25 0.5 <0.03–1.0 [35]
Cefotaxime 22 32 32 8.0–32 [36]
18 32 >64 16 to >64 [33]
Ceftriaxone 96 32 32 4.0–64 [37]
65 16 32 32 4.0–32 [35]
Ceftizoxime 22 32 32 16–64 [36]
Cefotetan 18 16 16 8.0 to >64 [33]
Ceftazidime 22 128 128 128–256 [36]
18 >64 >64 >64 [33]
Cefoperazone 22 2.0 4.0 0.5–4.0 [36]
Cefoxitin 96 8 32 1.0–64 [37]
Aztreonam 22 >128 >128 >128 [36]
18 >64 >64 >64 [33]
Gentamicin 22 0.06 0.125 0.03–0.25 [36]
18 2.0 2.0 1.0–4.0 [33]
70 0.12 0.12 0.06–0.5 [37]
96 0.15 0.5 0.12–5.0 [37]
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to propose the most accurate method to determine
in vitro activity against B. anthracis.
When comparing the microbroth dilution meth-
ods and E test strip methods for B. anthracis, it was
demonstrated that MICs obtained with the E test
were up to eight times lower than those obtained
with the reference methods [34,35].
Resistant mutants
Resistance can be developed experimentally to
most of the current antibacterial agents.
Rifampicin
In the population of various strains of B. anthracis,
formation of spontaneous rifampicin-resistant
mutants was detected at a rate of 108. The level
of rifampicin resistance in the mutants ranged
from 16 to 512 mg/L. The clones of the rifampi-
cin-resistant population of the virulent strain CH-7
were heterogeneous in their biological properties
[40]. Rifampicin-resistant mutants were selected
from UV-light-treated attenuated B. anthracis (strain
Ames pXO1-pXO2), and spontaneous rifampicin-
resistant mutants were also isolated on selective
media. Mutations conferring rifampicin resistance
are commonly due to mutations in the b-subunit of
RNA polymerase, encoded by the rpoB gene. These
mutations are located in four clusters in the N-
terminal section. The majority of mutations occur
in cluster I. Twelve amino acid positions are known
to interact directly with rifampicin. Mutations were
observed at four of these positions for B. anthracis.
Of four amino acid mutations surrounding the
rifampicin-binding pocket, two of these changes—
position 450 (Ser!Cys) and 468 (Lys!Gln)—are
unique for B. anthracis. There is a greater diversity
among UV-generated rifampicin-resistant B. anthra-
cis strains (positions 472, 468, 459, 467, 450, 453, 450,
454 and 467) than among spontaneously occurring
mutants (positions 454, 467 and 472). The sponta-
neous rate of resistance was estimated at 1.57 109
mutations/generation by a Luria–Delbru¨ck fluctua-
tion test [41,42].
Fluoroquinolones
In a serial passage study, the potential for ofloxacin
and doxycycline to select mutants of the vaccine
strain B. anthracis Sterne was investigated.
Repeated subcultures of B. anthracis Sterne
increased the MIC of ofloxacin on the 13th passage
from 0.20 mg/L to 0.80 mg/L. The MIC of 0.8 mg/
L was stable for the next five passages. However,
B. anthracis remains susceptible to ofloxacin
according to the available breakpoints (not given
for B. anthracis) [43] (Table 4).
B. anthracis Sterne was used to investigate the
selection of resistant mutants after 21 sequential
subcultures in subinhibitory concentrations of
doxycycline, ciprofloxacin, trovafloxacin, and gati-
floxacin. The number of passages required for
selection of resistant mutants varied from nine
(trovafloxacin) to 10 (ciprofloxacin and gatifloxa-
cin). Currently, the mechanism of resistance to
fluoroquinolones of B. anthracis is unknown.
After sequential passages with a single fluoro-
quinolone, each isolate was cross-resistant to other
fluoroquinolones. In this study, MICs were deter-
mined using a macrodilution method in brain–
heart infusion broth [44] (Table 4).
Table 3 continued
MIC (mg/L)
Compounds N 50 90 Range References
Streptomycin 22 2.0 4.0 1.0–4.0 [36]
18 4.0 8.0 4.0–16 [33]
70 1.0 1.0 0.5–4.0 [37]
96 1.0 1.0 0.5–2.0 [37]
Amikacin 22 0.03 0.06 0.03–0.06 [36]
18 2.0 2.0 1.0–2.0 [33]
Netilmicin 22 0.06 0.125 0.01–0.125 [36]
18 2.0 4.0 2.0–8.0 [33]
Tobramycin 18 2.0 4.0 1.0–16 [33]
22 0.25 1.0 0.25–1.0 [36]
Partly replaced by Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and
2000. Cavallo JD, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E. Antimicrob Agents Chemother 2002; 46:
2307–9.
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Doxycycline
In one study, no mutants were detected [43] after
18 passages, but in another study, after 14 pas-
sages, the initial MIC of 0.025 mg/L increased to
0.1 mg/L [44]. Strains resistant to doxycycline
have been reported [45].
Macrolides
The number of passages required for selection of
resistant mutants varied from four (erythromycin
A) to 14 (clarithromycin). Mutants resistant to
azithromycin were obtained after eight passages
[44] (Table 4).
Resistance to antibacterial agents
A constitutive cephalosporinase is often produced
by wild-type strains. Resistance to penicillins and
doxycycline has been reported, and these strains
are believed to have been engineered. B. anthracis
CH-7 harbors the penicillinase gene in the re-
pressedstate[46].Therehavebeenonlyafewreports
on penicillin G resistance in B. anthracis [46–48]. The
followingantibioticsarenaturallyinactiveagainstB.
anthracis: sulfamethoxazole, trimethoprim, cefurox-
ime, cefotaxime and other 2-amino-5-thiazolyl
cephems(suchasceftriaxone,ceftazidime, cefepime
and cefpirome), and aztreonam.
Sensitivity to penicillin G has been used as a
diagnostic tool to differentiate between B. anthracis
and B. cereus isolates [49–51].
In B. anthracis, there are at least two b-lactamases
which show more than 93% amino acid homology
to the class A and B enzymes of B. cereus [52]. The
main b-lactamase in B. anthracis seems to be a
chromosomal metalloenzyme (class B).
In a study performed using the Microscan
device, all B. anthracis isolates tested were suscep-
tible to penicillin G. In the same study, the hydro-
lysis was quantitatively investigated. The
hydrolysis speeds expressed in micromoles of b-
lactam hydrolyzed per minute were 1.98 103,
2.09 107, 1.72 106, 1.59 106, 1.95 107,
4.07 107, 2.0 107 and 1.0 107 for peni-
cillin G, cephaloridine, cefotaxime, cefuroxime,
cefazolin, imipenem, cephalexin and cephradine,
respectively, and the relative rates of hydrolysis
versus penicillin G (100) were 1.1, 8.7, 8.0, 0.99, 2.1,
1.0 and0.5 for cephaloridine, cefotaxime, cefur-
oxime, cefazolin, imipenem, cephalexin and
cephradine, respectively [52]. In Kruger National
park in South Africa, there is an area contaminated
with B. anthracis spores. The in vitro susceptibil-
ities of 44 B. anthracis isolates from this area were
assessed against 16 antibacterial agents using a
disk diffusion method in comparison with dia-
meter zones obtained with Staphylococcus aureus
NCTC 6571 on Mueller–Hinton agar according to
Ericsson and Sherris [53]. Sensitivity to penicillin
G, novobiocin and cefamandole was encountered
in 84.1%, 86.4% and 68.18% of the isolates, respec-
tively. Several isolates were moderately suscepti-
ble to penicillin G (15.9%), clindamycin (6.8%),
fusidic acid (84%), novobiocin (13.6%), and cefa-
mandole (31.8%) [54].
Animal models
The protective effects of ciprofloxacin, pefloxacin
and lomefloxacin were investigated in animal
anthrax induced with B. anthracis spores of three
vaccinal strains. Protection was 50–80%, 40–70%
and 40–70% for 10LD50, 100LD50 and 1000LD50,
respectively [55]. A high therapeutic efficacy of
minocycline was reported, irrespective of the con-
taminating dose and strains [45].
Table 4 MICs after sequential passages [43,44]
Antibacterial agent
Number of
subcultures
Initial MIC
(mg/L)
MIC at 21
subcultures
(mg/L)
Number of passages
required to
increase MIC
4-fold or greater
Ciprofloxacin 21 0.1 1.6 10
Trovafloxacin 21 1.6 12.5 9
Gatifloxacin 21 0.02 1.6 10
Ofloxacin 18 0.2 0.8 13
Doxycycline 21 0.02 0.1 14
Erythromycin A 15 6.25 6.25–50 4
Azithromycin 15 12.5 12.5–50 8
Clarithromycin 15 0.2 0.4–1.6 14
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Female Dunkin–Hartley guinea pigs (500–600 g)
were challenged for 7 min with aerosols of B.
anthracis spores of Ames strain or Vollum strain
to obtain a lung dose of 104106 spores. Animals
received either ciprofloxacin or doxycycline by the
subcutaneous route for 21 days after bacterial
exposure. Antibiotic levels were determined in
non-infected animals.
Doxycycline and ciprofloxacin protected ani-
mals from infection following inhalation of up
to 106 spores of both strains of B. anthracis, so long
as administration of the antibiotics was continued.
After antibiotic administration had been discon-
tinued, some animals died, more quickly in the
ciprofloxacin group than in the doxycycline group.
B. anthracis was isolated from the lung tissue of
these guinea pigs [56].
The in vivo efficacies of penicillin G, ofloxacin,
trovafloxacin and gatifloxacin were investigated
after B. anthracis challenge by the intratracheal
route 4 days after 60Co irradiation of female
B6D2AF 1/J mice (16–20 g). The endpoint was
the survival rate 30 days after challenge. The anti-
bacterial therapy was started 6, 24 and 48 h after
bacterial exposure, and continued for 7 or 21 days.
It was demonstrated that non-lethal irradiation
associated with a B. anthracis Sterne spore chal-
lenge increased the translocation of intestinal
microflora. Antibacterial treatment must start
within 24 h and be completed at 21 days to sig-
nificantly reduce the mortality rate after exposure
to B. anthracis Sterne following non-lethal irradia-
tion. The survival rates after therapy with trova-
floxacin, gatifloxacin, penicillin Gþ ofloxacin,
penicillin G and ofloxacin were 90%, 79%, 55%,
25% and 21%, respectively [57].
R A T I O N A L E F O R L O N G - T E R M
A N T I B I O T I C T R E A T M E N T
In inhalation anthrax, the mortality rate is high. In
the Sverdlovsk (Russia) outbreak, it was reported
that 66 of 79 patients died, although the reliability
of the diagnosis in the surviving patients is ques-
tionable. However, it seems that patients whose
onset of disease was 30 or more days after inhala-
tion had a higher rate of recovery in comparison
with those who had early onset of the disease. In
the case of fatalities, the interval between onset of
symptoms and death averaged 3 days. In mon-
keys, there is a similar course of the disease, even
after a latency of 58 days.
After inhalation of anthrax spores, the spore-
bearing particles of 1–5 mm were deposited in
alveolar spaces. The spores are engulfed by alveo-
lar macrophages, and many of them are able to
survive within their phagocytes, even if most of
them are lyzed. Surviving spores are transported
via the lymphatic system to mediastinal lymph
nodes, where germination may occur up to 60 days
later [58,59]. In the Sverdlovsk outbreak, clinical
onset occurred from 2 to 43 days after exposure. In
experimental monkeys, fatal disease occurred up
to 98 days after exposure. Viable spores have been
shown in the mediastinal lymph nodes of monkeys
100 days after exposure.
L I M I T S O F A N T I B I O T I C T H E R A P Y
Main characteristics needed for an antibacterial
agent to be efficacious against B. anthracis
Owing to the pathophysiology of inhaled anthrax,
the following studies are needed to determine
potential clinical efficacy and possible use of the
antibiotic for prevention after exposure to anthrax
spores:
1. In vitro activities, determined by a mean of MIC
values for a sufficient number of isolates col-
lected from human and animal sources.
2. Mutant selection needs to be investigated.
3. Bactericidal activity has to be determined.
4. Animal infections (rhesus monkeys, guinea
pigs, rabbits, and mice) must be assessed with
determinations of pharmacokinetic parameters
[60–62].
5. Determination of plasma levels in humans must
be assessed, as well as respiratory tissue levels
(bronchial mucosa, alveolar macrophages,
epithelial lining fluid).
6. Intracellular concentration and efflux in macro-
phages must be assessed as well as antibacterial
localization within the cell, B. anthracis being
mainly located in the phagolysosome; intracel-
lular bioactivity against this pathogen could be
investigated. Although B. anthracis is an extra-
cellular pathogen, it appears to require an intra-
cellular step to initiate infection.
7. B. anthracis spores and germination occur in the
lymph nodes [58,59]; determination of antibac-
terial levels at this site is therefore an important
parameter. However, when the capacity of the
lymph node is overwhelmed, the infection
spreads to successive nodes, and the bacilli then
enter the bloodstream and multiply.
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Only a few families of antibacterial agents
are able to concentrate in phagocytes: macrolides,
ketolides, fluoroquinolones, cyclines, ansamycins
(rifampicin and derivatives), streptogramins,
clindamycin, and teicoplanin [63]. To combat B.
anthracis, antibacterials need to be mainly concen-
trated in the phagolysosome. Data on lymph node
concentrations are scarce. Data are available for
ofloxacin [64], levofloxacin [65], pefloxacin [66],
ciprofloxacin [67], fleroxacin [68], azithromycin
[69], and doxycycline [70]. However, these studies
have been carried out mainly in mesenteric lymph
nodes for the treatment of typhoid fever.
B. anthracis
B. anthracis virulence depends on the bacterial
capsule and the toxin complex, which is composed
of three entities, a protective antigen, an edema
factor, and a lethal factor. The three components of
the anthrax toxin need to be associated for it to
exert its effect [71].
Oncegerminationoccurs,diseasefollowsrapidly.
Replicating organisms release toxins, leading to
hemorrhage, edema, and necrosis. In experimental
animals,once toxinproductionhasreacheda critical
threshold, death occurs even if sterility of the blood-
stream is achieved with antibiotics.
No immune response has been demonstrated in
experimental animals receiving antibiotic therapy
during anthrax infection. Experimental studies
demonstrated that treatment with penicillin G for
5–10 days,startingondayoneafteraerosolexposure
of monkeys, was protective during the course of
antibiotic treatment; however the monkeys died
when the treatment was discontinued. Long-term
protection was afforded only by combining penicil-
lin G therapy with post-exposure immunization.
Rhesus monkeys (Macaca mulatta) that survived
the aerosol challenge were examined for evidence
ofanimmuneresponse131–142 daysafterexposure,
by measuring antibody to the protective component
of anthrax toxin. No surviving animals treated with
penicillin G, ciprofloxacin or doxycycline alone had
an immune response. No protection was afforded
against rechallenge of the surviving monkeys [72].
This suggests that even if the antibiotic-treated
patients survive anthrax infection, the risk for recur-
rence remains for at least 60 days, due to the possi-
bility of delayed germination of spores. Post-
exposure vaccination in those patients may shorten
the duration of antibiotic therapy to 30–45 days.
T H E R A P Y F O R A N T H R A X
( A N T I B I O T I C S )
Cutaneous anthrax
It has been shown in cutaneous anthrax that nega-
tivation of blister fluid occurs 5 h after the first 2
million units of benzylpenicillin [73]. The standard
recommendation is 2 million units every 6 h intra-
venously until the edema subsides, at which time
oral penicillin (phenoxypenicillin or penicillin V)
therapy can be used. The duration of treatment is
at least 7–10 days.
Doxycycline, chloramphenicol, macrolides and
fluoroquinolone are considered to be alternative
therapies.
Antibiotic therapy does not stop the progress of
anthrax lesions to an eschar phase, but does
decrease systemic manifestations and local edema.
Inhalation anthrax
Aerosolized anthrax spores >5 mm in size are
deposited in the upper airways (pharynx, larynx,
and trachea), and effectively trapped or cleared by
the mucociliary system. Spores between 2 and
5 mm in size are able to reach the alveolar ducts
and alveoli. These spores are engulfed by alveolar
macrophages and transported to mediastinal and
hilar lymph nodes. In the phagocytes, B. anthracis
is located in the phagolysosome [71]. The mini-
mum infectious inhaled dose in humans has not
yet been determined. The minimum infectious
dose in chimpanzees is 40 000–65 000 spores [74].
The alveolar macrophages represent the primary
site of toxigenic B. anthracis germination during
infection by inhalation [75]. Early antibiotic
administration is essential, due to the rapid onset
of the disease (started from 12 h). A delay in anti-
biotic treatment for patients with anthrax infec-
tion, even for several hours, may substantially
lessen the chances of survival.
However, there are no clinical studies on the
treatment of inhalation anthrax in humans. No
data have been released from the Russian outbreak
[76], and there is only limited clinical experience
with the recent events [77]. In rhesus monkeys, a
major change occurred within 3–8 days after inha-
lation of a lethal dose. Hemorrhages are found in
mediastinal, mesenteric and tracheobronchial
lymph nodes, and small intestinal serosa [78].
In studies of small numbers of monkeys infected
with susceptible strains of B. anthracis, oral
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doxycycline proved efficacious. Doxycycline is the
preferred option in the cycline class being inves-
tigated for efficacy in animal models [79]. How-
ever, reports have been published of a B. anthracis
vaccine strain that has been engineered to be
resistant to tetracycline and benzylpenicillin. In
rhesus monkeys, after exposure to aerolized
spores of B. anthracis, administration of benzylpe-
nicillin was shown only to delay death in the
animals [80]. The delay was generally proportional
to the duration of penicillin G administration and
probably related to the low intracellular concen-
tration of b-lactam antibiotics.
Engineering of fluoroquinolone-resistant B.
anthracis may also be possible; however, there
are no published reports on this.
Even though only ciprofloxacin was licensed by
the FDA for this purpose in July 2000, a report
from the CDC in 1998 [81] recommended vaccina-
tion and the use of oral fluoroquinolones such as
ciprofloxacin, 500 mg bid, levofloxacin, 500 mg qd
or ofloxacin, 400 mg bid, for post-exposure pro-
phylaxis in adults.
C O N C L U S I O N
Although B. anthracis seems to be very susceptible
to penicillins, it is important to note that b-lactam
antibiotics are not concentrated in phagocytes.
In contrast, fluoroquinolones, macrolides, keto-
lides and cyclines are highly concentrated in the
cell. Long-term tolerance needs to be consid-
ered to allow patient compliance. In the recent
outbreak in the USA, 19% of the patients receiv-
ing prophylaxis complained of adverse events,
and about 5% discontinued their medication
[82]. Furthermore the selection of resistant mu-
tants is the risk to be highlighted during long-term
treatment. Antibacterial agents will significantly
decrease the bacterial burden; however, for inha-
lation anthrax, the main factor remains the intox-
ication, against which antibacterials are ineffective
[83].
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